Chimerix Inc (STU:CXF)
€ 3.03 0.21 (7.45%) Market Cap: 298.58 Mil Enterprise Value: 168.48 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 51/100

Chimerix Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 08, 2021 / 02:40PM GMT
Release Date Price: €4.98 (+2.77%)
Andrew E. Singer
Credit Suisse Group AG - MD of Healthcare Investment Banking Division

Good morning, everyone. This is Andy Singer at Credit Suisse. I want to welcome you to the Credit Suisse Annual Virtual Healthcare Conference. And I'm very pleased to introduce the management team of Chimerix. We have Mike Sherman, the CEO; Mike Andriole and Josh Allen, who is the Chief Technology Officer of Imipridones.

So I'll turn it over to Mike for the presentation.

Michael A. Sherman
Chimerix, Inc. - CEO, President & Director

Great, Andy. I appreciate you having us. It's always nice to present at this conference, it's particularly nice when we have some fresh clinical data -- positive clinical data to be able to share. So I look forward to probably a little bit more focus on that recent news than usual. Here we go. I will be making some forward-looking statements, so please refer to our most recent SEC disclosures for those risks and uncertainties.

I think we'd like to talk about something that we're doing that's unique here at Chimerix,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot